Samsung Group leader Lee Jae-yong, currently in the US, has vowed to make biotechnology the conglomerate’s second core strategic business after semiconductors.
After meeting with heads of global pharmaceutical firms, the chairman of Samsung Electronics Co., the world’s largest memory chip and smartphone maker, said Samsung, a latecomer to the biotech sector, will soon become a leader, particularly in the contract drug-making segment.
“The starting point is not important. With our bold and strong determination to meet challenges, we can make our biotech business another success story just as we did with semiconductors,” Lee said last week at a meeting with employees of Samsung Biologics Co.’s North American sales corporation.
“Let’s carry our success DNA with chips to the biotech realm.”
EXTENDED STAY IN US
The chairman, widely known in international business circles as Jay Y. Lee, is traveling in the US after joining the economic delegation of South Korean President Yoon Suk Yeol’s first state visit to Washington, D.C., in late April.
Researchers at Samsung Biologics' third plant in Songdo, Incheon During his extended US stay, Lee has been meeting with executives of Samsung’s clients, which include electronics, technology and biopharmaceutical firms, Samsung officials said.
He has met with Joaquin Duato, chief executive of Johnson & Johnson (J&J); Giovanni Caforio, CEO of Bristol Myers Squibb (BMS); Chris Viehbacher, CEO of Biogen Inc.; Kevin Ali, CEO of Organon & Co.; and Noubar Afeyan, Moderna Inc.'s co-founder and the CEO of Flagship Pioneereing, a biotech venture capital firm.
In meetings with biotech executives, Lee explored new business opportunities and sought to expand collaboration with them, Samsung officials said.
BMS is one of Samsung’s early clients. It placed drug consignment orders with Samsung Biologics in 2013, when it began manufacturing drugs under contract.
Samsung Biologics has manufactured Moderna’s messenger ribonucleic acid (mRNA)-based COVID-19 vaccine at its Korean plants.
Lee’s latest meeting with Moderna co-founder Afeyan comes less than two years after their previous meeting in November 2021.
Samsung Biologics' fourth plant under construction in Incheon, west of Seoul AIMS TO REPEAT THE SUCCESS OF CHIPS
Samsung Biologics has been ramping up its facilities to meet growing client demand.
Most biopharmaceutical companies such as Pfizer, Moderna, AstraZeneca, and Janssen — Johnson & Johnson’s pharmaceuticals division — focus on R&D. Lacking manufacturing facilities, they outsource production to contract drugmakers.
Samsung Biologics, the biotech unit of Korea’s top business group, has focused on manufacturing drugs for others in a scheme known as a contract manufacturing organization (CMO) since entering the biopharmaceuticals market in 2011.
The company now aims to solidify its leadership in the contract development and manufacturing organization (CDMO) segment, which involves cooperation from the drug development stage, which is more profitable.
Samsung Biologics' third plant in the Songdo area of Incheon In 2012, Samsung Group created another biopharmaceutical unit, Samsung Bioepis Co., which develops and produces biosimilar drugs for other companies.
Upon the launch of the fifth plant, Samsung’s drug manufacturing capacity will reach 784,000 liters, further widening its lead over rival contract drugmakers, Samsung officials said.
Last July, Samsung Biologics said it would double its manufacturing capacity by building four more plants costing 7 trillion won to become the world’s leader in both the CMO and CDO businesses.
The company posted 980 billion won in operating profit on 3 trillion won in sales in 2022.
The global CDMO market is steadily increasing, despite heightened competition. In particular, Samsung Biologics' focus of antibody drug manufacturing is seeing growing demand.
Samsung Biologics serves more than half the world’s top 10 drugmakers as their contract drugmaker.
